Compare Fox Corp Class B (FOX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Merck & Co., Inc. — how do they compare? Fox Corp Class B trades at $55.42 (market cap $25.05B), while Merck & Co., Inc. trades at $129.71 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 12.9× Fox Corp Class B's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| FOX | MRK | |
|---|---|---|
Market Cap | $25.05B | $323.00B |
Sector | Media | Health |
52-Week High | $67.76 | $131.84 |
52-Week Low | $44.39 | $77.60 |
Enterprise Value | $28.41B | $369.77B |
Dividend Yield | 1.03% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX stock trades at $57.03, up 3.0% in 24 hours, reflecting strong momentum. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 underscore robust performance, with revenue reaching $16.30 billion in 2025. Technical indicators signal bullish trends, supported by moving averages, while RSI levels suggest potential overbought conditions. The company maintains solid profitability with a net income margin of 9.84% and ROE of 14.29%, though valuation metrics like P/E of 14.84 appear reasonable relative to peers.
Outlook remains positive driven by ad demand and digital growth, including Tubi and FOX One initiatives. Risks include reliance on advertising cycles and competitive pressures. Analyst consensus leans neutral with 42.86% buy ratings, but recent news highlights operational strength. Investors should weigh earnings consistency against market volatility and sector headwinds.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
